Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

A better way of understanding protocol changes wit

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154853
(Total Views: 352)
Posted On: 07/02/2025 8:32:29 AM
Posted By: Plotinus
Re: chazzledazzle #154790
A better way of understanding protocol changes with the FDA would be to parse out an FDA approval to proceed with the study from subsequent amendments to protocol, which are not uncommon and often pretty minor; the FDA portal for protocol submission is versioning each and every change introduced by the sponsor. I would regard the inclusion and exclusion criteria along with Leronlimab treatment protocol as pivotal to have been under deep scrutiny to get to final approval by the FDA. The oncologist however is going to react to the clinical picture which emerges and if there surfaces an opening to add a PD-L1 inhibitor based on lab results they are probably not going to hesitate to do so unless it was specifically called out as an exclusion in the study. I suspect this would be considered a more minor change to the protocol and it would simply be adjusted by the study sponsor on the FDA portal with no subsequent objection by the FDA. The key thing is that Cytodyn added the lab to the study so that analysis of subgroups that might include PD-L1+ patients treated with Leronlimab and a PD-L1 blocker added in response to lab data can be scrutinized further as far as outcomes. Remember this is a phase 2 “exploratory” trial which is not just probing impact on defined primary and secondary endpoints but trying to lend additional credence to clinical impact by fleshing out the details related to purported mechanism of action.



(16)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us